Creating a market access strategy for Zulresso® /

Sage Therapeutics is a neuroscience-focused biopharmaceutical company founded in Cambridge, Massachusetts, in 2010. Their primary focus is on introducing innovative therapies and solutions for brain disorders. Zulresso®, Sage's only marketed product as of 2022, received its FDA approval under p...

Full description

Bibliographic Details
Main Authors:	Dasgupta, Swikriti (Author), Sharma, Taijasi (Author), Munshaw, Supriya (Author)
Format:	eBook
Language:	English
Published:	London : SAGE Publications: SAGE Business Cases Originals, 2023.
Series:	Sage business cases.
Subjects:	New products > Case studies. Business planning > Case studies. Business planning New products Electronic books. Case studies
Online Access:	Connect to the full text of this electronic book

Description
Summary:	Sage Therapeutics is a neuroscience-focused biopharmaceutical company founded in Cambridge, Massachusetts, in 2010. Their primary focus is on introducing innovative therapies and solutions for brain disorders. Zulresso®, Sage's only marketed product as of 2022, received its FDA approval under priority review in March 2019. Zulresso® is indicated for treating postpartum depression (PPD) in adults. This was the first medication indicated solely for this condition. Sage had to consider various commercial challenges in launching this product. This case will introduce students to some of these challenges through the concept of a market access strategy for a pharmaceutical product.
Physical Description:	1 online resource.
ISBN:	9781071915882 1071915886